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New developments in the ﬁeld of thoracic oncology have challenged the way pathologists approach the diagnosis of pulmonary
carcinoma. Nonsmall cell carcinoma is no longer an adequate diagnostic category. Pathologists are required to further classify
tumors into adenocarcinoma and squamous cell carcinoma since speciﬁc therapies are now recommended depending on the
histological tumor type. This change occurred following the discovery of speciﬁc molecular alterations that predict response to
certain drugs and now molecular testing of tumor cells is often requested to direct therapy. The vast majority of lung cancer is
diagnosed in advanced clinical stages, where cytologic or small biopsy material is the only form of tissue diagnosis, thus placing
cytology, especially ﬁne needle aspiration biopsy in the front line for management of patients with lung cancer. In this paper we
will review the current concepts in the suitability and accuracy of ﬁne needle aspiration biopsy, including diagnosis, classiﬁcation,
prognostic markers, and use of ancillary techniques.
1.Introduction
Pulmonary nodules discovered by an imaging technique
present a relatively frequent clinical problem. A solitary
pulmonary nodule is a common manifestation of a benign
condition. However, in nodules larger than 2cm, the inci-
dence of a primary lung cancer ranges from 64 to 82% [1].
An early, accurate diagnosis is of paramount importance
for initiating speciﬁc therapy for malignant lesions, and
for avoiding unnecessary procedures for benign conditions.
Thus, after clinical risk assessment tissue diagnosis is the
nextstepinmanagingradiologicallysuspiciouslungnodules.
Direct tissue sampling for diagnosis is essential in most
patients for decisions regarding treatment and can be
accomplished by ﬁne needle aspiration biopsy (FNAB),
endoscopic or core needle biopsy, or surgical resection.
Sampling of the lesion by FNAB can be performed via the
airway (endobronchial transbronchial FNAB) or chest wall
(CT-guided percutaneous FNAB). Transbronchial FNAB is
useful for the diagnosis of primary pulmonary lesions that
lie beneath the bronchial surface and for staging lung
cancer patients by sampling mediastinal lymph nodes. FNAB
has become recognized as a safe and eﬀective diagnostic
tool, as a result of improved aspiration biopsy tools and
techniques, better control of complications, and increased
experience of cytopathologists in interpreting aspirate speci-
mens.
Most patients with lung cancer present with clinical
advanceddiseaseandthereforearenotcandidatesforsurgery
with curative intent, but are rather treated with systemic
therapies. In the age of personalized therapies, cytological
material in the form of FNAB may be the only available
diagnostic specimen, and the only material available for
molecular studies, necessary for current therapeutic decision
making. New recommendations for screening of high-risk
populations [2] coupled with the ongoing development of
minimally invasive techniques and procedures for sampling
lung lesions will most likely further increase the need
for accurate diagnosis and molecular characterization of
malignant tumors on small biopsy specimens.
Inthispaper,wewillcovercurrentconceptsandadvances
in FNAB of pulmonary carcinomas including diagnosis,2 Pathology Research International
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Figure 1: The characteristic morphologic patterns of tumor in smears. (a) SQC carcinoma showing ﬂat sheet of polygonal, atypical cells and
(b) orangeophilia on Pap stain demonstrating keratinization. (c) ADC with typical cytomorphology and formation of glandular structures.
classiﬁcation, prognostic makers, and use of ancillary tech-
niques.
2. ClinicalAdvances inthe Management of
Patients with Pulmonary Carcinoma
The current classiﬁcation of lung cancer recognizes four
major histological subtypes, namely, squamous cell carci-
noma (SQC), adenocarcinoma (ADC), large-cell carcinoma
(LCC), and small cell lung carcinoma (SCLC). Until recently,
most of the cytological diagnosis of lung carcinoma was
based on distinguishing SCLC from other tumors generally
designated as nonsmall cell carcinoma (NSCLC), because
these two categories were the most relevant for directing
therapy. However, advances in thoracic medical oncology
have led to a paradigm shift in NSCLC diagnosis, resulting in
a new emphasis on accurate NSCLC subtyping. Speciﬁcally,
two novel agents have challenged NSCLC as clinically
relevant diagnostic category. It has been demonstrated that
patients with the diagnosis of SQC are at increased risk for
life-threatening complications if treated with bevacizumab,
a humanized antibody against vascular endothelial growth
factor (VEGF) [3]. In addition, in the case of pemetrexed,
an antifolate that inhibits multiple enzymes in purine
and pyrimidine synthesis, patients with SQC showed no
response to the drug in comparison to a good response
observed in patients with the diagnosis of non-squamous
cell carcinoma [4]. For these reasons, these two new drugs
are only recommended for use in patients with a diagno-
sis of non-squamous cell carcinoma. Other developments
include the identiﬁcation of genetic alterations which have
been described almost exclusively in adenocarcinoma that
confer susceptibility to therapeutic agents or resistance to
chemotherapeutic drugs. For example, tumors with epider-
m a lg r o w t hf a c t o r( EGFR) mutations have a better outcome
and respond to the tyrosine kinase inhibitors erlotinib and
geﬁtinib, as a ﬁrst-line therapy, whereas patients without
EGFR mutations seem to have a better outcome with
standard chemotherapy [5]. Furthermore, translocation in
the EML4-ALK gene has been described predominantly in
adenocarcinomas. This translocation confers susceptibility
to speciﬁc inhibitor, crizotinib that is currently undergoing
clinical testing [6].
These advances in the understanding of molecular
mechanisms underlying lung cancer and the development of
new targeted therapies challenge the traditional diagnostic
dichotomization between SCLC and NSCLC and prompt
a more speciﬁc characterization of NSCLC into squamous
or adenocarcinoma category. Traditionally, NSCLC sub-
classiﬁcation has been based on morphologic assessment
of routine H&E-stained histological specimens. Because
cytology specimens, such as FNAB, diﬀer in preparation
and technique from traditional histology, the accuracy of
subtyping these specimens has been challenged, yet there is
considerable evidence supporting the utility of cytology in
bothsubtypingNSCLCandprovidingmaterialforpredictive
and prognostic studies.
3. Role of ImmediateAssessment in the
Accuracy of LungFNA CytologicalDiagnosis
Published reports reveal that the sensitivity of FNAB for
the diagnosis of lung cancer ranges from 56 to over 90%
whereas speciﬁcity is close to 100%. In nearly all these
studies, the overall positive predictive value is nearly 99%.
While the false positive rate is generally less than 1%, a
negative result is less reliable with most studies reporting
a false negative rate of around 10% [7, 8]. The major
contribution to the relatively high false negative rate is
failure to obtain diagnostic material, most commonly due
to sampling error. Studies have shown that immediate on-
site assessment is valuable in minimizing false negative
diagnoses due to nondiagnostic material [9, 10]. Published
series by Austin and Cohen show that immediate on-site
assessment during FNAB was associated with a statistically
signiﬁcant increased diagnostic accuracy compared to cases
without immediate assessment, 100% versus 80%, respec-
tively [11]. During on site adequacy determination, smears
from the aspirate are rapidly stained and are evaluated
by a cytopathologist or cytotechnologist for cellularity and
diagnostic yield. On-site adequacy evaluation also pro-
vides real-time communication of information including
appropriate tissue triage recommendations for ancillary
tests such as molecular testing, ﬂow cytometry, cytoge-
netics, electron microscopy, and so forth. This interaction
directly impacts clinical management during the criticalPathology Research International 3
Table 1: Factors contributing to diﬃculty of cytologic subtyping of adenocarcinoma and squamous cell carcinoma.
N = 165 Cellularity Diﬀerentiation
(1) Histologic type
Low High Well-moderately Poorly ADC SQC
Correct deﬁnitive Subtyping (n = 148) 82% 94% 87% 69% 93% 70%
Diﬃculty in Subtyping (n = 17)
(2) 18% 6% 13% 31% 7% 30%
(1)Grade of diﬀerentiation was based on resected specimens.
(2)Diﬃculty in subtyping encompasses cases which were incorrectly classiﬁed, unclassiﬁed, or underclassiﬁed/subtype favored by cytology.




Morphology still remains the cornerstone in lung cancer
classiﬁcation. The World Health Organization classiﬁcation
of lung tumors through the 1999 edition did not address
lung cancer diagnosis based on small biopsies and cytology
[12]. In the 2004 World Health Organization classiﬁcation,
cytology was addressed for the ﬁrst time, with descriptions
of the morphological criteria for each type of pulmonary
carcinoma [13]. In the new revised proposal [14], an entire
section is dedicated to the classiﬁcation of lung tumors based
onsmallbiopsymaterialincludingFNAB.Thishighlightsthe
importance and recognition of the role that FNAB plays in
the diagnosis and management of pulmonary carcinomas.
Lung cancer histological subtypes that are morpholog-
ically recognizable on cytology specimens are ADC, SQC,
and SCLC, as well as carcinoid tumors. Other types of
lung carcinoma such as large cell carcinoma and other rare
variant as fetal type and colloid adenocarcinoma may be
suspected on the basis of pure morphology but usually
require evaluation of the surgically resected specimen for the
ﬁnal diagnosis.
Historically, it has been important to accurately identify
SCLC as the treatment is diﬀerent from NSCLC. Classical
morphological features of SCLC such as nuclear molding,
frequent mitoses, and absence of nucleoli are often distorted
on a small biopsy specimen showing extensive crush artifact.
In this setting, cytology has an edge over histology because
of better preservation and fewer artifacts [15]. Cytology is
highly accurate and a well-recognized method to distinguish
SCLC from NSCLC. In a study of 259 consecutive lung FNAs
by Delgado et al., SCLC was distinguished from NSCLC with
accuracy of 96% [16].
Unlike the distinction of SCLC and NSCLC, feasibility
of NSCLC subtyping in cytology has been controversial.
However, based on a recent study from our institution,
cytology provides several advantages over surgical specimens
for the subtyping of NSCLC [17]. The key morphologic
criteriaforADCversusSQCareglandulararchitectureversus
keratinization,respectively.ThePapanicolaou(Pap)stainhas
exquisite sensitivity for even minimal keratinization aiding
in the distinction of SQC from ADC. The morphologic
patterns which emerge in tumor smears provide a clue to
a tumor subtype which may not be apparent in surgical
Table 2: Sensitivity and speciﬁcity of cytologic tumor subtyping.
n = 183 Sensitivity Speciﬁcity Accuracy
SQC versus non-SQC 87% 98% 97%
ADC versus non-ADC 98% 79% 93%
specimens(Figure 1).Inaddition,duetoimmediateﬁxation,
cytology provides greater nuclear and cytoplasmic resolution
than histology. While in the majority of cases a line of
diﬀerentiation can be clearly identiﬁed by morphology,
diﬃculties arise in a subset of cases.
In a recent study, which included 165 cases with paired
FNAB and resection diagnosis of ADC and SQC, we
described some of the limiting factors for the interpreta-
tion and accurate classiﬁcation in cytology specimens. The
strongest predictors for diﬃculty in subtyping were poor
diﬀerentiation of the tumor where distinguishing morpho-
logic features are not apparent (Table 1), followed by scant
cellularity. Nonkeratinizing poorly diﬀerentiated squamous
cell carcinoma in particular is subject to misclassiﬁcation by
FNAB [18]. Another diﬃculty is presented by tumors with
mixed histology, but true adenosquamous carcinomas are
infrequent with reported incidence of 2 to 3% in published
surgical series [19].
Despite these limitations, using morphology and occa-
sional immunocytochemistry we observed that when faced
with the need to subclassify NSCLC we performed with
high concordance between cytology and resected specimens
of 97% and 93% for identifying squamous and adenocar-
cinoma, respectively (Table 2). Despite the lower sensitivity
for non-keratinizing SQC, the speciﬁcity of this diagnosis is
very high, which means that the false-positive classiﬁcation
as SQC is extremely rare. Thus having proved overall high
accuracy of cytology in distinguishing SQC versus non-SQC
it was concluded that cytological specimens are suitable
for guiding therapeutic decisions within these diagnostic
categories [18].
5. Use of Immunohistochemistry Stainsinthe
Characterization of NSCLC Subtypes
In tumors that do not show clear-cut signs of diﬀerentiation
on light microscopy examination (Figure 2) further investi-
gation by immunohistochemistry may highlight tumor cell
lineage. In biopsies like FNAB, with limited material, the
need to conserve material for possible mutational analysis
and other prognostic markers obligates the use of the most4 Pathology Research International
Figure 2: Poorly diﬀerentiated carcinoma lacking clear signs of
diﬀerentiation on light microscopic examination. Further work up
usinglimitedpanelofantibodieswilldiﬀerentiatetumorcelllineage
in the majority of cases.
eﬃcient and limited panel of immunohistochemical stains.
Several recent publications have addressed the question
of what is the best panel of markers to be used in
the distinction between adenocarcinomas and squamous
cell carcinoma. Results published by Wu et al. showed
the advantages of immunocytochemistry in distinguish-
ing poorly diﬀerentiated SQC from SCLC of the lung,
and primary adenocarcinoma from metastatic tumors in
cytology specimens. In their study, all poorly diﬀerentiated
squamous cell carcinomas showed expression of p63 while
negative for thyroid transcription factor-1 (TTF-1), whereas
adenocarcinomas had the opposite staining pattern. Of note,
SCLC had identical p63/TTF-1 expression proﬁle as adeno-
carcinoma, but application of standard morphologic criteria
and addition of neuroendocrine markers was suﬃcient for
accurate classiﬁcation [20]. Nicholson et al., in their recently
published work that included 13 FNA cytology specimens,
showed that a limited panel of TTF-1, CK5/6, and p63
together with a mucin stain, reﬁned diagnosis of NSCLC to
either ADC or SQC in 65% of cases [21].
In summary, most of the work has been concentrated
on the expression of 3 markers TTF-1, p63, and a high-
molecular-weight cytokeratin (HMWCK). The following
algorithm, based on published data and our experience can
guide the interpretation of the stains. A TTF-1 negative/p63-
positive/HMWCK-positive proﬁle is supportive of SQC,
whereas any expression of TTF-1 is supportive of ADC. It
is worth mentioning that coexpression of TTF-1 and p63 can
be seen in adenocarcinomas. In most cases p63 expression
in adenocarcinoma is patchy and weak. Negative staining
for both p63 and TTF-1 usually rules out squamous cell
carcinoma [22].
Napsin-A is an aspartic proteinase, involved in the
maturation of the surfactant protein B and is expressed
in the cytoplasm of cells of lung and kidney [23]. The
staining is cytoplasmic and is strongly positive in up to
80% of primary lung adenocarcinomas. In the study of
Stoll et al., 75 cytology cases were analyzed. It showed that
the sensitivity and speciﬁcity of TTF-1 were each 81%.
Napsin-A exceeded the speciﬁcity of TTF-1 at 96% with a
lower sensitivity of 65%. In the study, the only carcinoma
of nonlung origin in which Napsin-A was detected was
renal cell carcinoma, suggesting that Napsin-A can be used
as a surrogate marker in work up of poorly diﬀerentiated
lung adenocarcinoma or an unknown primary tumor [24].
Desmocolin-3, constitutive protein of desmosomes, is found
to be overexpressed in SQC of the lung [25, 26]. In the study
by Monica et al., which included 31 cytological specimens
originallyclassiﬁedasNSCLC,stainingfordesmocolin-3and
TTF-1 was mutually exclusive in tumors [26].
Several authors reported on the high sensitivity and
speciﬁcity of miRNA expression in SQC of the lung, and
its usefulness in diﬀerentiating ADC from SQC in small
specimens [27, 28]. However, a recently published study
does not support this observation [29]. The utility of these
new approaches compared to standard markers needs to
be evaluated further and validated, since a limited panel
of immunohistochemical markers can reproduce the results
obtained by the new molecular techniques [22].
6. Adequacyof MaterialObtainedby
FNAB for Molecular Testing
In the recent years we have witnessed a revolution in our
understanding of the molecular basis of NSCLC. These
advances have led to development of multitude of com-
mercially available prognostic and predictive biomarkers
and targeted therapeutic agents. Despite these advances in
treatment, the overall prognosis remains poor in patients
with advanced disease. Personalizing therapy based on an
individual tumor molecular proﬁle can optimize eﬃcacy
with the available agents. Molecular determinants that
guide treatment decision-making may have a prognostic
or predictive function, and are commonly referred to as
prognostic or predictive markers, respectively. Prognostic
marker refers to a tumor characteristic that is useful for
estimating a patient’s outcome independent of therapeutic
decisions. In contrast, predictive markers are useful in
making therapeutic decisions. Mutations of EGFR, KRAS,
and EML4/ALK translocations are mutually exclusive in lung
ADC and identify tumor subsets with unique dependencies
and drug sensitivities. KRAS mutation testing is utilized
by some institutions to exclude EGFR mutations or an
EML4/ALK translocation.
InparticularEGFRmutationandEML4/ALK fusiongene
testing have reached clinical validation and are incorporated
intothecurrenttreatmentparadigm[30].EML4/ALK testing
also appears to have clinical utility in identifying patients
who could beneﬁt from referral for a study targeting ALK
inhibition, such as ongoing phase 3 studies of the small
molecule tyrosine kinase inhibitor crizotinib.
There is increasing awareness that the quality of speci-
mens, such as cytology, has a profound inﬂuence on molec-
ular diagnostic test results. FNAB samples are exposed to a
greater variety of cytopreparation methods than resected tis-
sue and sample size and heterogeneity may have an eﬀect on
the downstream molecular test results [31]. Most molecular
techniques including in situ hybridization, polymerase chain
reaction (PCR), and transcriptional proﬁling can be done
on FNAB specimens [32, 33]. Optimizing and standardizingPathology Research International 5
of FNAB sample preparation methods is needed to preserve
biomolecular integrity to enable seamless integration into
molecular testing.
At present, there are few studies that rigorously compare
the cellular composition of FNA samples with the quantity
and quality of the desired analyte (DNA, mRNA, or protein)
or the robustness of the biomarker test utilizing the sample.
Schuurbiers et al. in their study conclude that molecular
testing of EGFR and KRAS on cytologic material obtained
byendobronchialultrasound-guidedtransbronchialFNABis
feasible and could be performed on 77% of their specimens
[34]. Another study by Smouse et al. showed that 67% of
cytology specimens were adequate for molecular testing with
some of the samples having as little as 25% tumor cellularity
[35].
We have found that in a large screen of various cytologic
specimens (FNABs, eﬀusions, and exfoliative specimens)
submitted for EGFR or KRAS mutational testing, 98% of
samples were suitable for analysis. We concluded that testing
is feasible and that with rare exception all cell blocks subjec-
tivelyinterpretedas“adequate”fordiagnosisbyapathologist
yieldedsuﬃcientquantityandqualityofDNAformutational
analysis. This ﬁnding is in agreement with several other
studies [18]. In a study of consecutive specimens from our
institution, it was found that 79% of cytology specimens
and 89% of small biopsy specimens submitted for molecular
testing were suﬃciently cellular [36] .T h er a t eo fEGFR and
KRASmutationsdetectedincytologicspecimensinthestudy
was comparable to the rate detected in surgical specimens.
7. Use of FNAB for Prognostic Markers
The reported incidence of local or distant recurrence
following surgical resection of early-stage NSCLC is around
36% [37]. The risk of recurrence is clearly linked to clinical
stage but further biomarkers predictive of tumor recurrence
are needed. A histological grading system based on the
predominant histological patterns seen in pulmonary ade-
nocarcinoma has been described recently [38]. In that study,
patients with stage 1 pulmonary adenocarcinoma could be
accurately stratiﬁed according to risk of recurrence of death
of the disease into 3 tiers representing low, intermediate
and high risk, thus indicating that an objective system of
tumor grade had prognostic signiﬁcance. In cytological
material however, there was no reliable corresponding
pattern of cellular aggregates to predict a histological pattern
for the same tumor [39], therefore a grading system based
on nuclear features has been developed and evaluated in
FNAB of pulmonary adenocarcinoma. The cytology grading
system is based on the nuclear size of neoplastic cells;
pattern of chromatin distribution; and nuclear contour and
it separates stage 1 pulmonary adenocarcinomas into two
groups. Tumors with low nuclear scores show a lower risk of
recurrence or death of the disease in contrast to tumors with
high nuclear scores [40]. In conclusion, FNAB can provide
signiﬁcant prognostic information to clinicians managing
patients with pulmonary adenocarcinoma.
EGFR mutations are the best predictor of response
to EGFR kinase inhibitors in pulmonary adenocarcinoma.
Recently, two antibodies that detect speciﬁcally mutated
EGFRproteinshavebecomecommerciallyavailable.Arecent
study from our institution demonstrated that these antibod-
ies show sensitivity of 95% for the detection of EGFR L858R
mutation, and sensitivity of 85% for the detection of exon 19
deletions. They concluded that immunohistochemistry for
mutated EGFR could be used as a screen method to identify
candidates for therapy with EGFR tyrosine-kinase inhibitors
[41].
An antibody that correlates with ALK gene rearrange-
ment in NSCLC has also been reported recently with promi-
sing results [42, 43] however this antibody is not yet com-
mercially available.
The use of these antibodies in cytological material has
not yet been validated, but they may oﬀer an invaluable tool
for screening patients with lung cancer where cytological
material is the only specimen available.
8.New SamplingMethods inLungFNAB
(EBUS and ENB)
A couple of new minimally invasive procedures have
been recently developed as an alternative to standard
approaches. One of them, endobronchial ultrasound-guided
transbronchial needle aspiration (EBUS-TBNA) has recently
emerged as a valid minimally invasive method for mediasti-
nal staging of lung cancers and diagnostic workup of cen-
trally located masses [44]. When used to sample mediastinal
lymph nodes, at least a moderate number of lymphocytes
must be present to ensure the adequacy of the specimen
and avoid a false negative result. A large retrospective study
performed at our institution found that EBUS-TBNA had
89% sensitivity and 100% speciﬁcity for malignant disease,
revealing no major discrepancies between tumor subtypes
rendered by EBUS-TBNA cytology and histology [45]. A
study by Turnoy et al. showed that in patients with NSCLC
without extrathoracic metastasis, EBUS-TBNA reduces the
need for surgical staging by 68% with lower incidence of
complications and no diﬀerence in diagnostic performance,
thus establishing the procedure as a valid alternative to
mediastinoscopy [46].
The two major limitations of standard ﬂexible bron-
choscopy are its inability to reach peripheral segments of
the lung and the limited diagnostic yield from lesions less
than 3cm in diameter. The alternative to bronchoscopy is
CT-guided percutaneous biopsy where the possible compli-
cations include hemorrhage and pneumothorax. Recently
developed technology that is emerging in clinical practice
essentially combines these two methods. Electromagnetic
navigation is a localization device that assists in placing
endobronchial accessories (e.g., forceps, brush, and needle)
in the desired areas of the lung. The system uses low
frequency electromagnetic waves and real-time 3D digital
reconstruction of the previously obtained CT scan of the
bronchial tree. Electromagnetic navigational bronchoscopy
(ENB) systems were recently cleared by the US Food
and Drug Administration to aid the physician in guid-
ing endoscopic tools in the respiratory tract. This novel
technical advance localizes and samples lesions in the lung6 Pathology Research International
parenchyma and mediastinum that are beyond the reach of
standard endoscopy [47]. Recent published studies showed
the diagnostic yield of ENB for small peripheral lung lesions
are in the range from 54% to 77%. Lamprecht et al. studied
ENB sampling using rapid on site cytological evaluation
duringtheprocedureanditshowedsensitivityandspeciﬁcity
of84.6% and100%, respectively. Citing potential drawbacks,
they found that 33.3% of the cases with ENB sampling were
falsely negative and deﬁnitive diagnosis had to be established
by CT-guided biopsy or by surgery [48]. Of note, other
authors have reported that presence of cytologist virtually
eliminates the problem of inadequate samples [49, 50].
9. Conclusion
The ﬁeld of thoracic oncology is going through a revolution
with the advent of targeted therapy for the management
of patients with lung cancer. FNAB is in many cases the
only diagnostic specimen available for guiding therapeutic
decisions. FNAB has proven to be an invaluable tool not
only for diagnostic accuracy of pulmonary carcinomas
classiﬁcation, but also as a reliable and adequate source of
material suitable for molecular analysis.
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